Pharsight

Twyneo generic

Twyneo is an anti-acne drug owned by Galderma Labs Lp. The active ingredients in Twyneo are Benzoyl Peroxide and Tretinoin, and it comes in the form of a topical cream. The drug was first authorized for market use on 26 July, 2021 and now holds 5 patents.

When will Twyneo generic be available?

The generic version of Twyneo is not yet available in the market due to active patents. The last patent is set to expire on 12 July, 2038, after which the release of Twyneo generics can be expected. Particularly, US10420743 that focuses on methods and compositions for the treatment of acne plays a significant role in this delay.

Twyneo uses

Twyneo is commonly used for the topical treatment of acne vulgaris in both adults and pediatric patients aged 9 years and above. The effectiveness of the drug is derived from its active ingredients, Benzoyl Peroxide and Tretinoin, which combine to reduce acne inflammation and promote the healing of acne lesions.

Twyneo patent expiration

Twyneo holds 5 patents that significantly contribute to the delayed release of its generics. Particularly, the latest patent, US10420743, which pertains to the treatment of acne will expire on 12 July, 2038. Below are the details of the patents:

Twyneo dosage

Want to ask something?